ZLB Rhophylac Clears FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
ZLB Bioplasma will make its IGIV product Rhophylac available in the U.S. in March, the company said
You may also be interested in...
FDA Cites ZLB's Rhophylac Promotions For Risk Info Omissions
ZLB is revising a Rhophylac website and has discontinued a sales brochure and patient Q&A cited in the warning letter issued by the Center for Biologics Evaluation & Research. The "main parts" of the promotions did not include sufficient risk information, FDA says.
Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says
The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.